From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
By T. Litman, T. Druley, W. Stein, S. Bates. Cellular and Molecular Life Sciences (CMLS), 2001
707 citations recorded by the source corpus.
Subfields: Infectious Diseases, Oncology, Pediatrics, Perinatology and Child Health
View Paper: https://www.semanticscholar.org/paper/d2e67408953fc3bf5c61d37f66d81b072cfe5cf5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Oncology
In Pediatrics, Perinatology and Child Health
Citations in the corpus
- Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) (2003, background): “Reviews of the role of BCRP in drug resistance of clinical cancers are available (Bates et al., 2001; Litman et al., 2001; Ejendal and Hrycyna, 2002).”
- P-glycoprotein: from genomics to mechanism (2003, background): “Subsequently, other members of this family of transporters such as MRP1 (ABCC1) and MXR (ABCG2) have been shown to be capable of conferring MDR by virtue of energydependent drug efflux (reviewed in Litman et al., 2001; Borst and Elferink, 2002; Gottesman et al., 2002).”
- ABC multidrug transporters: structure, function and role in chemoresistance. (2008, background): “However, three ABC proteins appear to account for most observed multidrug resistance in humans and rodents; Pgp (ABCB1, MDR1), MRP1 (ABCC1) and breast cancer resistance protein ABCG2 (variously known as BCRP, ABCP or MXR) [7].”